Visiopharm A/S Overview
Pro stress-test →Visiopharm is a leading provider of AI-driven precision pathology software for research, diagnostics, and biopharmaceutical services. The company combines 20 years of knowledge working with pathologists and research scientists with AI to provide accuracy and versatility for tissue analysis challenges in research and diagnostics. In diagnostics, it is a leader within clinical applications, with no fewer than nine diagnostic algorithms cleared under IVDR for EU and UK customers.
Strategic Profile
Pro stress-test →Founded in 2002, Denmark-based Visiopharm operates internationally with over 750 customer accounts in more than 40 countries. Grundium Oy, a leader in advanced digital scanning backed by US-based healthcare private equity firm EW Healthcare Partners, announced the acquisition of Visiopharm A/S in (May 2026). By combining Grundium's scanner portfolio with Visiopharm's AI-driven software, the platform supports a broad range of use cases, from individual laboratory workflows to enterprise-scale deployments, biomarker development, translational research, clinical studies, and companion diagnostic programs.
Competitive Landscape
Pro stress-test →Visiopharm competes in the AI-driven digital pathology software market against platforms like PathAI (AISight), Indica Labs (HALO), and Proscia (Concentriq). Key differentiation includes 24+ years of domain expertise, nine IVDR-cleared diagnostic algorithms, and strong partnerships enabling interoperability across imaging systems and laboratory workflows.
Industry Context
Visiopharm A/S operates in AI-driven digital pathology software.
Key facts
Founded: 2002 · Headquarters: Hørsholm, Denmark